Definition and Epidemiology
Klippel–Trenaunay syndrome (KTS; OMIM #150800) is a rare, non-hereditary congenital disorder characterized by a triad of features:

1. Capillary malformation (port-wine stain)
2. Venous malformations and/or venous anomalies
3. Soft tissue and/or bone overgrowth (limb hypertrophy)

Incidence is estimated at 1–5 per 100,000 live births, with no sex or ethnic predilection. KTS is considered a vascularOVERGROWTH spectrum disorder and is now classified under the broader entity PIK3CA-Related Overgrowth Spectrum (PROS), reflecting its molecular pathogenesis.

Etiology and Pathophysiology

Molecular Genetics

• Recent advances confirm that ~80–90% of KTS cases harbor somatic mosaic gain-of-function mutations in the PIK3CA gene (phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha), located on chromosome 3q26.32.
• These mutations lead to constitutive activation of the PI3K-AKT-mTOR signaling pathway, resulting in dysregulated cell growth, proliferation, metabolism, and vascular morphogenesis (Ng et al., Nat Genet 2014; Lindhurst et al., Am J Hum Genet 2015).
• Mosaicism explains the segmental, asymmetric presentation—mutations are typically undetectable in leukocytes; analysis of affected tissue (e.g., surgical specimen) or highly sensitive next-generation sequencing (NGS) of laser-captured microdissected lesions is often required.

Historical Hypotheses Revisited

• Sympathetic ganglia injury hypothesis: Largely discredited due to lack of histopathological evidence.
• Deep venous obstruction hypothesis: While deep venous anomalies (e.g., absence or hypoplasia of the femoral or iliac veins) are common and contribute to venous hypertension, they are secondary to developmental malformation—not acquired thrombosis.
• Mesodermal/ectodermal dysplasia: Outdated; modern molecular evidence supports a mesenchymal stem cell–driven developmental disorder with aberrant vascular and lymphatic specification.

Clinical Manifestations

Cardinal Features (Triad)

1. Capillary Malformation (Port-Wine stain)
   • Present in >95% of cases, usually involving the affected limb(s).
   • Classically dermatomal or somatic, often extending into the foot/hand. May darken and nodulize over time (pyogenic granuloma-like changes).
   • Diagnostic clue: The stain’s distribution often maps to the affected limb segment—helpful in differentiating from Sturge–Weber (trigeminal V1) or Parkes–Weber (diffuse capillary malformation with high-flow shunt).
2. Venous Malformations & Anomalies
   • Present in >90%: Includes
     • Absent, hypoplastic, or dilated deep veins (e.g., femoral, iliac)
     • Persistent embryonic venous channels (e.g., sciatic vein)
     • Varicosities at unusually young age (<10 years)
     • Venous valves agenesis/dysgenesis → chronic venous insufficiency
   • Critical distinction: KTS typically lacks arteriovenous shunting—if high-flow lesions are present, consider Parkes–Weber syndrome (KTS without capillary malformation + AVMs).
3. Soft Tissue and Bone Overgrowth
   • Limb length discrepancy (LLD) in ~80%, usually lower limb (>2 cm clinically significant).
   • Hypertrophy of muscle, fat, connective tissue → limb bulk asymmetry.
   • Orthopedic complications: Scoliosis, joint hypermobility, pes planus, hip dysplasia.

Lymphatic Involvement (~30–60% of cases)

• Lymphatic malformations (microcystic/macrocytic), lymphedema (often progressive in adolescence/adulthood), recurrent cellulitis.
• May mimic isolated lymphatic disorders; combined venolymphatic anomalies complicate management.

Other Associated Features

Diagnosis: A Multimodal Approach

Clinical Suspicion

• Diagnosis requires ≥2 cardinal features.
• Differentiate from mimics:
  • Parkes–Weber syndrome: capillary malformation + high-flow AV shunts + LLD (often more severe overgrowth).
  • CLOVES syndrome: truncal/limb overgrowth, macrodactyly, lumbar lipoma—PIK3CA-related but distinct PROS.
  • Maffucci syndrome: enchondromas + spindle cell hemangioendothelioma.

Imaging & Investigations

Note: Echocardiogram is not routine unless cardiac output compromise suspected (e.g., large limb involvement + high-output heart failure).

Management: Evidence-Based Strategies

Multidisciplinary Care is Mandatory

Team: Vascular anomalies specialist, hematologist, orthopedics, dermatology, genetics, physical medicine/rehab.

Medical Management

• Anticoagulation:
  • Indicated for acute DVT/PE or high-risk features (previous thrombosis, central venous access, severe venous insufficiency).
  • DOACs (e.g., rivaroxaban, apixaban) are preferred over warfarin (better safety profile in chronic use) (Rogers et al., J Thromb Haemost 2021).
  • Prophylaxis: Not routinely recommended; consider during high-risk periods (immobilization, surgery).
• Compression Therapy:
  • First-line for venous insufficiency/lymphedema.
  • Graduated compression stockings (30–40 mmHg at ankle); custom-fit due to asymmetry.
  • Evidence: Reduces edema, pain, skin changes; improves function (Ballester et al., JAMA Dermatol 2020).

Interventional/Surgical Options

Emerging Therapies

• PI3Kδ/γ Inhibitors (e.g., duvelisib): Early case reports show reduced pain, edema, and lesion volume (Gniadecki et al., JAMA Dermatol 2023).
• mTOR Inhibitors (e.g., sirolimus): Used off-label for complex lymphatic anomalies; limited KTS data but promising in PROS (Bale et al., N Engl J Med 2022).
• Allogeneic CAR-T cells targeting PIK3CA-mutant cells: Preclinical stage.

Prognosis and Long-Term Risks

• Life Expectancy: Near-normal with proactive management.
• Mortality Risks:
  • Pulmonary embolism (1–3% lifetime risk)
  • Massive hemorrhage from trauma to fragile varicosities
  • Sepsis from recurrent cellulitis in lymphedematous limbs
• Morbidity Drivers:
  • Chronic pain, skin ulcers, functional impairment
  • Psychological burden: Body image issues (especially adolescents), anxiety about progression

Key guideline: Annual comprehensive assessment including: limb length, venous Doppler US, D-dimer (if suspected thrombosis), skin/soft tissue exam, mobility/function evaluation.

Special Considerations: Pregnancy and Surgery

• Pregnancy:
  • Increased venous stasis → 2–3× higher DVT risk. Prophylactic anticoagulation often indicated from 1st trimester (ACOG 2023).
  • Labor/delivery planning: Avoid prolonged supine position; epidural caution if spinal vein anomalies.
• Surgical Risks:
  • Excessive bleeding from malformed vessels
  • Wound dehiscence due to tissue hypoxia
  • Preoperative: Coagulation workup, avoid arterial puncture in affected limb.

Summary for Clinicians

KTS is a mosaic PIK3CA-driven vascular OVERGROWTH disorder requiring individualized, lifelong management. Early recognition prevents complications (e.g., DVT, ulceration). Multidisciplinary care, advanced imaging, and emerging targeted therapies have transformed outcomes. Refer to a vascular anomalies center for optimal management.

References:

• Lindhurst et al. Am J Hum Genet. 2015;96(2):230–240.
• Rogers et al. JAMA Dermatol. 2020;156(7):758–766.
• Bale & Webber. N Engl J Med. 2022;386:1309–1320.
• Ballester et al. JAMA Dermatol. 2020;156(10):1141–1148.
• International vascular anomalies classification (ISVAN, 2018; updated 2023).